Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.

Area of Science:

• Oncology
• Neurology
• Pharmacovigilance

Background:

• Mitoxantrone is an immunomodulatory drug used for multiple sclerosis.
• Therapy-related risks of secondary malignancies are a concern with long-term immunosuppressive treatments.

Purpose of the Study:

• To evaluate the risk of developing malignancies in patients treated with mitoxantrone for multiple sclerosis.
• To compare cancer incidence in this cohort against the general population.

Main Methods:

• Retrospective cohort study of mitoxantrone-treated multiple sclerosis patients (1994-2007).
• Follow-up data collected until 2010, including medically confirmed malignancies.
• Cancer rates compared to the German national cancer registry.

Main Results:

• 37 malignancies (5.5%) observed in 676 patients over 6,220 person-years.
• Standardized incidence ratio (SIR) for all malignancies was 1.50.
• Significantly increased SIR for colorectal cancer (2.98) and acute myeloid leukemia (10.44).
• Higher age at treatment initiation was a risk factor; cumulative dose and other immunosuppressants were not.

Conclusions:

• Mitoxantrone therapy is associated with a mild overall increase in malignancy risk.
• A notable heightened risk exists for colorectal cancer and leukemia.
• Post-therapy colonoscopy screening may be advisable for these patients.